Analysis of Complications in Outpatient ICD Surgery On or Off Warfarin Anticoagulation.

BACKGROUND: Implantable cardioverter defibrillator (ICD) implantation is being performed differently at many hospitals, with some keeping patients overnight after procedure while others discharge patients home same day. In addition, many centers are now performing ICD surgery while on warfarin anticoagulation. There are, however, limited data on outpatient ICD surgery on anticoagulated (AC) patients. OBJECTIVE: We wished to evaluate the safety of performing outpatient ICD surgery with and without warfarin anticoagulation. METHODS: We evaluated 866 patients who underwent outpatient ICD surgery between April 2010 and September 2014. Patients who were on novel oral anticoagulants, or did not have an international normalized ratio drawn within 24 hours of the procedure were excluded and the remainder were divided into two groups based on whether they were on (n = 230) or off (n = 518) warfarin anticoagulation. We evaluated both procedural and 30-day complications in both groups. RESULTS: The complication rate at 30 days in the warfarin AC group was 4.3%, while in the nonanticoagulated (NAC) group was 2.9% and not significantly different (P = 0.31). However, the pocket hematoma rate in the warfarin anticoagulated group was 3.5%, as compared to the NAC group that was 0.4% (P = 0.001). CONCLUSION: Complications from ICD surgery are low in the ambulatory setting on or off warfarin anticoagulation and appear to be comparable. However, warfarin use during ICD surgery is associated with an increased risk of pocket hematoma.

A prospective study comparing the sensed R wave in bipolar and extended bipolar configurations: the PropR study.

BACKGROUND: Progress in implantable cardiac defibrillator (ICD) technology has allowed for switching the sensing polarity for the detection of ventricular fibrillation (VF). However, whether one sensing polarity confers additional advantage over the other is not known. OBJECTIVES: To determine whether one sensing polarity is superior to the other for the detection of VF. METHODS: Patients were enrolled into a prospective randomized study of sensing of VF and R waves in normal rhythm. Sensing of VF was determined by number of under sensed beats (USB), and time to detection of VF (TDVF). Each patient underwent ICD implantation followed by testing of the ICD. At each induction, patients were randomized to sensing in extended bipolar (EBP) or true bipolar (TBP) configuration. Additionally, R waves were compared at implant and at 1-month follow-up. RESULTS: A total of 50 patients were enrolled into the study. When evaluating the primary endpoint, no difference was found between USB in EBP or TBP configuration; 1.1 ± 1.2 beats versus 1.3 ± 1.3 beats; P = NS. Also, no difference was found between TDVF in EBP or TBP configurations; 5.9 ± 0.6 seconds versus 5.9 ± 0.6 seconds; P = NS. With regard to the secondary endpoints, there was no difference between R waves in EBP or TBP configurations at the time of implant 10.9 ± 4.8 mV versus 10.9 ± 4.8 mV P = NS; or at 1-month follow-up 12.4 ± 4.7 mV versus 12.0 ± 5.4 mV P = NS. CONCLUSIONS: There is no difference in the detection of VF between EBP or TBP configurations in patients undergoing ICD implantation.

Advanced heart block and atrial flutter in a patient with HLA B27 spondyloarthropathy.

An athletic 43-year-old man presented with symptomatic bradycardia and atrial flutter after being diagnosed with HLA B27 associated spondyloarthropathy several months earlier. The patient was admitted and underwent electrophysiology evaluation with ablation of his atrial flutter and eventually underwent pacemaker implantation. His cardiac workup showed a structurally normal heart and strongly suggested that his HLA B27 associated spondyloarthropathy was responsible for his presentation. A review of the literature suggests that HLA B27 spondyloarthropathy related heart block may be an often overlooked cause of heart block in otherwise healthy patients.

The monolithic fetal pacemaker: prototype lead design for closed thorax deployment.

Prenatal sudden cardiac death and hydrops fetalis are often due to complete heart block. However, no pacing modality exists for intrauterine application for fetal bradycardia. A prototype lead for a novel fetal pacemaker has been developed and used in a direct pacing model. It has been demonstrated that the lead can be safely and successfully deployed using a hypochondriac and transdiaphragmatic or subxiphoid approach. Pacing with ventricular capture was evident with the widening of QRS duration from 50.2 +/- 9.8 to 95.1 +/- 12.8 ms (P = 0.0001). Further studies by echocardiogram revealed an increase in the pulse with pacing, confirming pacing. This study documents proof-of-concept for closed thorax over-the-wire deployment of a novel lead design applicable to fetal pacing. By combining the lead design with microcircuitry and a small power source, it is possible to create a monolithic fetal pacemaker system capable of being deployed in utero.